Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL

Cell Cycle

Volumn 11, Issue 6, 2012, Pages 1174-1182

  Mojic, Marija ^a   Mijatovic, Sanja ^a   Maksimovic Ivanic, Danijela ^a   Dinic, Svetlana ^a   Grdovic, Nevena ^a   Miljkovic, Djordje ^a   Stosic Grujicic, Stanislava ^a   Tumino, Salvatore ^b   Fagone, Paolo ^b   Mangano, Katia ^b   Zocca, Mai Britt ^c   Al Abed, Yousef ^d   McCubrey, Jim ^e   Nicoletti, Ferdinando ^b,c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF CATANIA   (Italy)

^c OncoNox   (Denmark)

^d North Shore Long Island Jewish Health System ^*  (United States)

^e EAST CAROLINA UNIVERSITY   (United States)

Author keywords

S6 protein; Saquinavir; Saquinavir NO; TRAIL; XIAP

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN S6; SAQUINAVIR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; XENOGRAFT;

EID: 84858725994     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.6.19611     Document Type: Article

References (42)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-92; PMID:17287242; http://dx.doi.org/10.1093/annonc/mdl498.
2. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008; 11:17-24; PMID:18374623; http://dx.doi.org/10.1016/j.drup.2008.02.001.
3. Wu GS. TRAIL as a target in anti-cancer therapy. Cancer Lett 2009; 285:1-5; PMID:19299078; http:// dx.doi.org/10.1016/j.canlet.2009.02.029.
4. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007; 26:3745-57; PMID:17530027; http://dx.doi.org/10.1038/sj.onc.1210374.
5. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997; 16:2794-804; PMID:9184224; http://dx.doi.org/10. 1093/emboj/16.10.2794.
6. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17:1675-87; PMID:9501089; http://dx.doi.org/10.1093/emboj/17.6.1675.
7. Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 2009; 8:838-42; PMID:19221505; http:// dx.doi.org/10.4161/cc.8.6.7906.
8. Finnberg N, El-Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. [Review]. Cell Cycle 2008; 7:1525-8; PMID:18469516; http:// dx.doi.org/10.4161/cc.7.11.5975.
9. Barrett RM, Colnaghi R, Wheatley SP. Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro. Cell Cycle 2011; 10:538-48; PMID:21252625; http://dx.doi.org/10.4161/cc.10.3.14758.
10. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11:255-60; PMID:10209153; http://dx.doi.org/10.1016/ S0955-0674(99)80034-9.
11. Kataoka T, Schröter M, Hahne M, Schneider P, Irmler M, Thome M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs and gamma irradiation. J Immunol 1998; 161:3936-42; PMID:9780161.
12. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274:1541-8; PMID:9880531; http://dx.doi.org/10.1074/jbc.274.3.1541.
13. Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, et al. Inhibition of death receptor-mediated gene induction by a cycloheximide- sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J Biol Chem 2000; 275:24357-66; PMID:10823821; http:// dx.doi.org/10.1074/jbc.M000811200.
14. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276:10767-74; PMID:11278284; http://dx.doi.org/10. 1074/jbc.M005196200.
15. Seol JW, Lee YJ, Kang HS, Kim IS, Kim NS, Kwak YG, et al. Wortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through downregulation of IAP-2 protein. Exp Oncol 2005; 27:120-4; PMID:15995629.
16. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ. Interleukin-8 signaling attenuates TRAIL-and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008; 7:2649-61; PMID:18790747; http://dx.doi.org/10.1158/1535-7163.MCT-08-0148.
17. Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 2010; 15:1256-69; PMID:20582477; http://dx.doi.org/10.1007/s10495-010-0521-9.
18. Panner A, Parsa AT, Pieper RO. Use of APO2L/ TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev Anticancer Ther 2006; 6:1313-22; PMID:17020463; http://dx.doi.org/10.1586/14737140.6.9.1313.
19. Lakshmikanthan V, Kaddour-Djebbar I, Lewis RW, Kumar MV. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. Int J Cancer 2006; 119:221-8; PMID:16450389; http:// dx.doi.org/10.1002/ijc.21824.
20. Jeon KI, Rih JK, Kim HJ, Lee YJ, Cho CH, Goldberg ID, et al. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett 2003; 544:246-51; PMID:12782325; http://dx.doi.org/10. 1016/S0014-5793(03)00473-3.
21. Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender RP, et al. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumor cells. Endocr Relat Cancer 2011; 18:277-85; PMID:21317202; http://dx.doi.org/10.1530/ERC-10-0108.
22. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7:1745-62; PMID:18594202; http:// dx.doi.org/10.4161/cc.7.12. 6166.
23. Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, et al. Inhibition of SREBP1 sensitizes cells to death ligands. Oncotarget 2011; 2:186-96; PMID:21406729.
24. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277:145-53; PMID:8990341; http://dx.doi.org/ 10.1001/jama.1997.03540260059037.
25. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009; 10:61-71; PMID:19111246; http://dx.doi.org/10. 1016/S1470-2045(08)70334-6.
26. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumor growth. Lancet Oncol 2003; 4:537-47; PMID:12965274; http://dx.doi.org/10.1016/S1470-2045(03)01192-6.
27. Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, et al. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Mol Cancer Ther 2009; 8:1169-78; PMID:19417156; http://dx.doi.org/10.1158/1535-7163.MCT-08-0998.
28. Mijatovic S, Maksimovic-Ivanic D, Mojic M, Timotijevic G, Miljkovic D, Mangano K, et al. Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells. J Cell Physiol 2011; 226:1803-12; PMID:21506111; http://dx.doi.org/10.1002/jcp.22513.
29. Donia M, Maksimovic-Ivanic D, Mijatovic S, Mojic M, Miljkovic D, Timotijevic G, et al. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 2011; 10:492-9; PMID:21270522; http://dx.doi.org/10.4161/cc.10.3.14727.
30. Canducci F, Ceresola ER, Saita D, Al-Abed Y, Garotta G, Clementi M, et al. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. Antiviral Res 2011; 91:292-5; PMID:21763726; http://dx.doi.org/10. 1016/j.antiviral.2011.07.001.
31. Cornforth AN, Davis JS, Khanifar E, Nastiuk KL, Krolewski JJ. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 2008; 27:4422-33; PMID:18391984; http://dx.doi.org/10.1038/onc.2008.80.
32. Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011; 10:3948-56; PMID:22071574; http://dx.doi.org/10.4161/cc.10.22.18124.
33. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005; 25:8809-23; PMID:16199861; http://dx.doi.org/10.1128/MCB.25.20.8809-23.2005.
34. Avni D, Shama S, Loreni F, Meyuhas O. Vertebrate mRNAs with a 5'-terminal pyrimidine tract are candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element. Mol Cell Biol 1994; 14:3822-33; PMID:8196625.
35. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 2004; 279:288-98; PMID:14576150; http:// dx.doi.org/10.1074/jbc. M310821200.
36. Back JH, Kim AL. The expanding relevance of nuclear mTOR in carcinogenesis. Cell Cycle 2011; 10:3849-52; PMID:22067472; http://dx.doi.org/ 10.4161/cc.10.22.18329.
37. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011; 2:538-50; PMID:21730367.
38. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3:192-222; PMID:21422497.
39. Holcik M, Korneluk RG. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation. Mol Cell Biol 2000; 20:4648-57; PMID:10848591; http://dx.doi.org/10.1128/MCB.20.13.4648-57.2000.
40. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997; 410:78-82; PMID:9247127; http://dx.doi.org/10.1016/S0014- 5793(97)00323-2.
41. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16:3693-704; PMID:9218810; http:// dx.doi.org/10.1093/emboj/16.12.3693.
42. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5; PMID:5432063; http://dx.doi.org/10.1038/227680a0.